Media stories about Cambrex (NYSE:CBM) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cambrex earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.7868799266874 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of equities analysts recently weighed in on the stock. ValuEngine raised shares of Cambrex from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. BidaskClub downgraded shares of Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Finally, Craig Hallum reissued a “buy” rating and issued a $60.00 price target (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $62.33.
Cambrex (NYSE:CBM) opened at $49.65 on Tuesday. The firm has a market cap of $1,627.41, a PE ratio of 15.66, a P/E/G ratio of 1.11 and a beta of 2.26. Cambrex has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.
Cambrex (NYSE:CBM) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.08. The company had revenue of $112.60 million for the quarter, compared to the consensus estimate of $108.44 million. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The firm’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.47 EPS. analysts anticipate that Cambrex will post 2.97 EPS for the current year.
In related news, CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $54.96, for a total value of $219,840.00. Following the sale, the chief executive officer now directly owns 87,328 shares in the company, valued at approximately $4,799,546.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.48% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cambrex (CBM) Getting Somewhat Favorable Press Coverage, Report Finds” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2017/12/12/cambrex-cbm-getting-somewhat-favorable-press-coverage-report-finds.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related companies with MarketBeat.com's FREE daily email newsletter.